Nephrotoxicity of polymyxins: Is there any difference between colistimethate and polymyxin B?

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 3, 2017, Pages

  Zavascki, Alexandre P ^a,b   Nation, Roger L ^c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Acute kidney injury; Colistimethate; Colistin; Polymyxin B; Toxicodynamics

Indexed keywords

COLISTIMETHATE; COLISTIN; CREATININE; MEGALIN; POLYMYXIN B; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID; PRODRUG;

ACUTE KIDNEY FAILURE; ARTICLE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; HOSPITAL COST; HUMAN; KIDNEY FUNCTION; KIDNEY HOMOGENATE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; LENGTH OF STAY; MORTALITY RISK; NEPHROTOXICITY; PRIORITY JOURNAL; THERAPEUTIC INDEX; ACUTE KIDNEY INJURY; ANALOGS AND DERIVATIVES; ANIMAL; BACTERIAL INFECTIONS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; KIDNEY; MICROBIOLOGY; MORTALITY; MOUSE; PATHOLOGY; RAT; SURVIVAL ANALYSIS; TRANSPORT AT THE CELLULAR LEVEL;

ACUTE KIDNEY INJURY; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; COLISTIN; HUMANS; KIDNEY; MICE; POLYMYXIN B; PRODRUGS; RATS; SURVIVAL ANALYSIS;

EID: 85014283729     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02319-16     Document Type: Article

References (52)

1. Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 59:88-94. https://doi.org/10.1093/cid/ciu213.
2. Gales AC, Jones RN, Sader HS. 2011. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 66:2070-2074. https://doi.org/10.1093/jac/dkr239.
3. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2015. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. Diagn Microbiol Infect Dis 83:379-381. https://doi.org/10.1016/j.diagmicrobio.2015.08.013.
4. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1953-1958. https://doi.org/10.1128/AAC.00035-06.
5. Barnett M, Bushby SR, Wilkinson S. 1964. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 23:552-574. https://doi.org/10.1111/j.1476-5381.1964.tb01610.x.
6. Kelesidis T, Falagas ME. 2015. The safety of polymyxin antibiotics. Expert Opin Drug Saf 14:1687-1701. https://doi.org/10.1517/14740338.2015.1088520.
7. Sorli L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. 2013. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13:380. https://doi.org/10.1186/1471-2334-13-380.
8. Forrest A, Silveira FP, Thamlikitkul V, Garonzik SM, Mandragos K, Shoham S, Paterson DL, Li J, Nation RL. 2014. Toxicodynamics for colistinassociated changes in creatinine clearance, abstr A-038a. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC. http://gm.asm.org/.
9. Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. 2015. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 70:3291-3297. https://doi.org/10.1093/jac/dkv267.
10. Nation RL, Garonzik SM, Li J, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, Turnidge JD, Forrest A, Silveira FP. 2016. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis 62:552-558. https://doi.org/10.1093/cid/civ964.
11. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2015. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15:225-234. https://doi.org/10.1016/S1473-3099(14)70850-3.
12. Eadon MT, Hack BK, Alexander JJ, Xu C, Dolan ME, Cunningham PN. 2013. Cell cycle arrest in a model of colistin nephrotoxicity. Physiol Genomics 45:877-888. https://doi.org/10.1152/physiolgenomics.00076.2013.
13. Dai C, Li J, Tang S, Li J, Xiao X. 2014. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents Chemother 58:4075-4085. https://doi.org/10.1128/AAC.00070-14.
14. Azad MA, Finnin BA, Poudyal A, Davis K, Li J, Hill PA, Nation RL, Velkov T. 2013. Polymyxin B induces apoptosis in kidney proximal tubular cells. Antimicrob Agents Chemother 57:4329-4335. https://doi.org/10.1128/AAC.02587-12.
15. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 53:837-840. https://doi.org/10.1093/jac/dkh167.
16. Couet W, Gregoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89:875-879. https://doi.org/10.1038/clpt.2011.48.
17. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 47:1766-1770. https://doi.org/10.1128/AAC.47.5.1766-1770.2003.
18. Ma Z, Wang J, Nation RL, Li J, Turnidge JD, Coulthard K, Milne RW. 2009. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother 53:2857-2864. https://doi.org/10.1128/AAC.00030-09.
19. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. https://doi.org/10.1093/cid/cit334.
20. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. 2012. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 56:4625-4629. https://doi.org/10.1128/AAC.00280-12.
21. Moestrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE, Norris K, Gliemann J, Christensen EI. 1995. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 96:1404-1413. https://doi.org/10.1172/JCI118176.
22. Suzuki T, Yamaguchi H, Ogura J, Kobayashi M, Yamada T, Iseki K. 2013. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother 57:6319-6324. https://doi.org/10.1128/AAC.00254-13.
23. Abdelraouf K, Chang KT, Yin T, Hu M, Tam VH. 2014. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother 58:4200-4202. https://doi.org/10.1128/AAC.02557-14.
24. Dagil R, O'Shea C, Nykjaer A, Bonvin AM, Kragelund BB. 2013. Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: insight from the nmr structure of the 10th complement type repeat domain alone and in complex with gentamicin. J Biol Chem 288:4424-4435. https://doi.org/10.1074/jbc.M112.434159.
25. Ocheltree SM, Shen H, Hu Y, Keep RF, Smith DE. 2005. Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther 315:240-247. https://doi.org/10.1124/jpet.105.089359.
26. Lu X, Chan T, Xu C, Zhu L, Zhou QT, Roberts KD, Chan HK, Li J, Zhou F. 2016. Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. J Antimicrob Chemother 71:403-412. https://doi.org/10.1093/jac/dkv340.
27. Yousef JM, Chen G, Hill PA, Nation RL, Li J. 2011. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 55:4044-4049. https://doi.org/10.1128/AAC.00328-11.
28. Manchandani P, Zhou J, Ledesma KR, Truong LD, Chow DS, Eriksen JL, Tam VH. 2016. Characterization of polymyxin B biodistribution and disposition in an animal model. Antimicrob Agents Chemother 60: 1029-1034. https://doi.org/10.1128/AAC.02445-15.
29. Yun B, Azad MA, Wang J, Nation RL, Thompson PE, Roberts KD, Velkov T, Li J. 2015. Imaging the distribution of polymyxins in the kidney. J Antimicrob Chemother 70:827-829. https://doi.org/10.1093/jac/dku441.
30. Azad MA, Roberts KD, Yu HH, Liu B, Schofield AV, James SA, Howard DL, Nation RL, Rogers K, de Jonge MD, Thompson PE, Fu J, Velkov T, Li J. 2015. Significant accumulation of polymyxin in single renal tubular cells: a medicinal chemistry and triple correlative microscopy approach. Anal Chem 87:1590-1595. https://doi.org/10.1021/ac504516k.
31. Christensen EI, Birn H, Storm T, Weyer K, Nielsen R. 2012. Endocytic receptors in the renal proximal tubule. Physiology (Bethesda) 27: 223-236. https://doi.org/10.1152/physiol.00022.2012.
32. Daniel H, Rubio-Aliaga I. 2003. An update on renal peptide transporters. Am J Physiol Renal Physiol 284:F885-F892. https://doi.org/10.1152/ajprenal.00123.2002.
33. Falagas ME, Kasiakou SK. 2006. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10:R27. https://doi.org/10.1186/cc3995.
34. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. 2014. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58:2740-2746. https://doi.org/10.1128/AAC.02476-13.
35. Roberts KD, Azad MA, Wang J, Horne AS, Thompson PE, Nation RL, Velkov T, Li J. 2015. Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant Gram-negative bacteria. ACS Infect Dis 1:568-575. https://doi.org/10.1021/acsinfecdis.5b00085.
36. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. 2009. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 65:431-434. https://doi.org/10.1016/j.diagmicrobio.2009.07.018.
37. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57:1300-1303. https://doi.org/10.1093/cid/cit453.
38. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. 2014. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43: 349-352. https://doi.org/10.1016/j.ijantimicag.2013.12.002.
39. Rigatto MH, Oliveira MS, Perdigao-Neto LV, Levin AS, Carrilho CM, Tanita MT, Tuon FF, Cardoso DE, Lopes NT, Falci DR, Zavascki AP. 2016. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother 60: 2443-2449. https://doi.org/10.1128/AAC.02634-15.
40. Vardakas KZ, Falagas ME. 16 September 2016. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents https://doi.org/10.1016/j.ijantimicag.2016.07.023.
41. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294. https://doi.org/10.1128/AAC.01733-10.
42. European Medicines Agency. 24 October 2014, posting date. Polymyxincontaining medicines. Polymyxin Article 31 referral - Annex III Amendments to relevant sections of the summary of product characteristics and the package leaflets. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/Polymyxin-31/WC500176332.pdf.
43. European Medicines Agency. 5 January 2015, posting date. Assessment report on polymyxin-based products. Referral under Article 31 of Directive 2001/83/EC. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/Polymyxin-31/WC500179664.pdf.
44. Barrantes F, Tian J, Vazquez R, Amoateng-Adjepong Y, Manthous CA. 2008. Acute kidney injury criteria predict outcomes of critically ill patients. Crit Care Med 36:1397-1403. https://doi.org/10.1097/CCM.0b013e318168fbe0.
45. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. 2005. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16:3365-3370. https://doi.org/10.1681/ASN.2004090740.
46. Bellomo R, Kellum JA, Ronco C. 2012. Acute kidney injury. Lancet 380: 756-766. https://doi.org/10.1016/S0140-6736(11)61454-2.
47. Chawla LS, Eggers PW, Star RA, Kimmel PL. 2014. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 371:58-66. https://doi.org/10.1056/NEJMra1214243.
48. Waikar SS, Winkelmayer WC. 2009. Chronic on acute renal failure: longterm implications of severe acute kidney injury. JAMA 302:1227-1229. https://doi.org/10.1001/jama.2009.1364.
49. Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, Costa LW, Zavascki AP. 2015. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 70:1552-1557. https://doi.org/10.1093/jac/dku561.
50. Yousef JM, Chen G, Hill PA, Nation RL, Li J. 2012. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67:452-459. https://doi.org/10.1093/jac/dkr483.
51. Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, Nation RL, Li J, Thamlikitkul V. 2015. Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother 59:3224-3232. https://doi.org/10.1128/AAC.00280-15.
52. Dalfino L, Puntillo F, Ondok MJ, Mosca A, Monno R, Coppolecchia S, Spada ML, Bruno F, Brienza N. 2015. Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis 61:1771-1777. https://doi.org/10.1093/cid/civ717.